- Home
- SBRA vs GKOS Comparison
SBRA vs GKOS Comparison
Compare SBRA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- GKOS
- Stock Information
- Founded
- SBRA 2010
- GKOS 1998
- Country
- SBRA United States
- GKOS United States
- Employees
- SBRA N/A
- GKOS N/A
- Industry
- SBRA Real Estate Investment Trusts
- GKOS Medical/Dental Instruments
- Sector
- SBRA Real Estate
- GKOS Health Care
- Exchange
- SBRA Nasdaq
- GKOS Nasdaq
- Market Cap
- SBRA 4.6B
- GKOS 5.4B
- IPO Year
- SBRA N/A
- GKOS 2015
- Fundamental
- Price
- SBRA $17.60
- GKOS $85.61
- Analyst Decision
- SBRA Hold
- GKOS Strong Buy
- Analyst Count
- SBRA 8
- GKOS 13
- Target Price
- SBRA $20.63
- GKOS $120.38
- AVG Volume (30 Days)
- SBRA 3.0M
- GKOS 755.1K
- Earning Date
- SBRA 10-30-2025
- GKOS 10-29-2025
- Dividend Yield
- SBRA 6.82%
- GKOS N/A
- EPS Growth
- SBRA 236.12
- GKOS N/A
- EPS
- SBRA 0.76
- GKOS N/A
- Revenue
- SBRA $734,008,000.00
- GKOS $432,953,000.00
- Revenue This Year
- SBRA $7.36
- GKOS $28.90
- Revenue Next Year
- SBRA $8.76
- GKOS $25.57
- P/E Ratio
- SBRA $23.15
- GKOS N/A
- Revenue Growth
- SBRA 10.21
- GKOS 26.70
- 52 Week Low
- SBRA $15.60
- GKOS $77.10
- 52 Week High
- SBRA $20.03
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- SBRA 31.99
- GKOS 49.54
- Support Level
- SBRA $17.47
- GKOS $82.19
- Resistance Level
- SBRA $18.21
- GKOS $86.74
- Average True Range (ATR)
- SBRA 0.32
- GKOS 3.15
- MACD
- SBRA -0.08
- GKOS 0.44
- Stochastic Oscillator
- SBRA 9.82
- GKOS 64.17
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.